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Abstract 
The objective of this study was to investigate the impact of different hydrophobic ion 
pairs (HIP) on the oral bioavailability of the model drug octreotide in pigs. 
Octreotide was ion paired with the anionic surfactants deoxycholate, decanoate and 
docusate differing in lipophilicity. These hydrophobic ion pairs were incorporated in 
self-emulsifying drug delivery systems (SEDDS) based on BrijO10, octyldodecanol, 
propylene glycol and ethanol in a concentration of 5 mg/ml. SEDDS were 
characterized regarding size distribution, zeta potential, stability towards lipase, log 
DSEDDS/release medium and mucus diffusion behavior. The oral bioavailability of octreotide 
was evaluated in pigs via LC-MS/MS analyses. 
Most efficient ion pairing was achieved at a molar ratio of 1:3 (peptide : surfactant). 
SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair 
exhibited a mean droplet size of 152 nm, 112 nm and 191 nm and a zeta potential of 
-3.7, -4.6 and -5.7 mV, respectively. They were completely stable towards 
degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, 
respectively. The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 
and 0.17 x 10-9 cm2 /sec, respectively. In vivo studies with these HIPs showed no 
improvement in the oral bioavailability in case of octreotide-decanoate. In contrast, 
octreotide-deoxycholate and octreotide-docusate SEDDS resulted in a 17.9-fold and 
4.2-fold higher bioavailability vs. control. 
According to these results, hydrophobic ion pairing could be identified as a key 
parameter for SEDDS to achieve high oral bioavailability.  
Keywords: self-emulsifying drug delivery systems, octreotide, lipase stability, in-vivo 
study, drug release  
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1. Introduction 
Oral delivery of biologicals is a great challenge due to various physiological barriers 
including the enzymatic barrier (1), the mucus barrier (2) and the absorption 
membrane barrier (3). Especially, peptides show low bioavailability after oral 
administration due to enzymatic degradation and low intestinal permeability. Within 
recent years, hydrophobic ion pairing (HIP) emerged as valuable tool to improve the 
lipophilic character of peptide drugs in order to protect them towards enzymatic 
degradation by intestinal peptidases (4) and to improve their membrane permeability 
(5). Furthermore, due to hydrophobic ion pairing therapeutic peptides can be 
incorporated in self-emulsifying drug delivery systems (SEDDS) (6). Lipase stable 
SEDDS provide an even more pronounced protective effect for incorporated HIPs 
towards intestinal peptidases (7). Moreover, SEDDS can pass the mucus gel barrier 
in a comparatively more efficient manner (8) and are known for their permeation 
enhancing properties (9). So far, promising in vivo results could be obtained by 
hydrophobic ion pairing of the peptide leuprolide (4) and of the low molecular weight 
heparin enoxaparin (10) being incorporated into SEDDS. In case of leuprolide an 
even 17.2-fold increase in oral bioavailability in rats compared to an aqueous 
solution was achieved (4). However, the full potential of SEDDS containing HIPs for 
oral delivery of biologicals has by far not been reached, as various key parameters 
were not addressed within previous studies. One of these key parameters is likely 
the type of hydrophobic ion pairing that has not yet been investigated in a 
comparative study at all. Moreover, important in vivo data regarding oral delivery of 
SEDDS containing a hydrophobically ion paired peptide drug are only available for 
rodents and a proof of concept in a non-rodent model is still missing. 
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It was therefore the aim of this study to generate three different ion pairs with a 
model peptide drug and to compare their performance in vitro and in vivo. Octreotide 
was chosen as model peptide drug as it is of high clinical relevance (11) and data of 
phase III clinical trials with orally administered octreotide are already available (12). 
After hydrophobic ion pairing with the anionic surfactants deoxycholate, decanoate 
and docusate, octreotide was incorporated into SEDDS. These SEDDS were 
evaluated in vitro in terms of biodegradability by lipase, drug release, log 
DSEDDS/release medium, mucus permeation and permeation enhancing effect. Finally, in 
vivo studies were performed with these formulations in pigs. 
 
2. Materials and Methods 
2.1. Materials 
Ammonium acetate, Brij O10, calcium chloride, ethanol 96 % (v/v), fluorescein 
dextran (FD4), formic acid, glucose, 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES), heptafluorobutyric acid (HFBA), magnesium sulfate, 
liquid paraffin, lumogen red, octyldodecanol, potassium chloride, propylene glycol, 
sodium chloride, sodium deoxycholate, sodium docusate, sodium decanoate and 
Tween® 80 were obtained from Sigma-Aldrich, Vienna, Austria. Acetic acid, 
acetonitrile, BD Vaccutainer EDTA tubes, methanol and water HPLC grade were 
supplied by VWR Austria. Amicon Ultra® centrifugational filters were received from 
Merck Millipore Darmstadt, Germany. Miglyol 840 was obtained from IOI Oleo GmbH 
(Hamburg, Germany). Octreotide acetate was purchased from Bachem AG, 
Bubendorf, Switzerland. The internal standard octreotide-D8 was obtained from 
Toronto Research Chemicals (Toronto, Ontario, Canada). 
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2.2. Methods 
2.2.1. HPLC analysis of octreotide 
Octreotide acetate was quantified using RP-HPLC. In brief, samples were analyzed 
on a YMC-Pack C4 column (250 × 4.6 mm, 5 μm, 30 nm pore size) using isocratic 
elution and a flow rate of 1 ml/min. The mobile phase consisted of 80% A (10% 
acetonitrile, 89.9% water, 0.1% formic acid, 2 mM ammonium acetate) and 20% B 
(90% acetonitrile, 9.9% water, 0.1% formic acid, 2 mM ammonium acetate). For 
quantification, a calibration curve with increasing amounts of octreotide acetate (10-
500 µg/ml) was established. 
 
2.2.2. Hydrophobic ion pairing of octreotide 
Lipophilicity of octreotide acetate was increased via hydrophobic ion pairing as 
already described previously (4). For this purpose, the ion pairing agents, namely 
sodium deoxycholate, sodium decanoate and sodium docusate were dissolved 
separately in a concentration of 5 mg/ml in demineralized water. Thereafter, the 
solution of the respective anionic surfactant was added dropwise to a 5 mg/ml 
solution of octreotide acetate under continuous stirring. The resulting suspensions of 
precipitated ion pairs were centrifuged at 10000 rpm at 10 °C (Sigma laboratory 
centrifuge 3-18 KS). The supernatant was analyzed for unbound octreotide acetate 
via HPLC as described above. The precipitated pellet containing the ion pair was 
lyophilized at reduced pressure (Christ Gamma 1-16 LSC Freeze dryer) and stored 
at -20 °C until further use. 
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2.2.3. Preparation of SEDDS 
In order to prepare SEDDS which are likely stable towards enzymatic degradation by 
lipases, only ingredients without ester substructures were utilized according to a 
previous study, but with modifications (7). Therefore, Brij™O10, octyldodecanol and 
paraffin were chosen as emulsifier and oily components, respectively. Furthermore, 
propylene glycol and ethanol were added as co-solvents. The excipients were mixed 
in different ratios as listed in Tab. 1, vortexed and incubated at 40 °C under constant 
shaking at 1000 rpm (Thermomixer comfort, Eppendorf, Germany) for 2 hours, 
whereby semisolid components were melted in advance. For analytical reasons 
lumogen red was optionally added in a final concentration of 0.1% (m/v).  
Octreotide loaded SEDDS were prepared by incorporating octreotide-deoxycholate 
in SEDDS B3, octreotide-decanoate in SEDDS B4 and octreotide-docusate SEDDS 
B6 as listed in Tab. 1. In brief, 5 mg of each ion pair was dissolved in 1 ml of the 
respective SEDDS pre-concentrate via heating to 40 °C for 5 minutes followed by 
short ultra-sonication for 10 minutes.  
In order to characterize SEDDS, 100 µl of SEDDS pre-concentrates were emulsified 
in 10 ml 100 mM phosphate buffer pH 6.8 and analyzed regarding mean droplet size 
and zeta potential via dynamic light scattering (Zeta Potential/Particle Sizer, 
Nicomp™ 380 ZLS, PSS, Santa Barbara, CA, USA) with laser wavelength of 650 nm 
and an E-field strength of 5 V. For determination of the zeta potential emulsions were 
prepared with demineralized water instead of phosphate buffer to exclude effects of 
the buffer. 
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2.2.4. Lipase degradation studies  
In order to evaluate the stability of SEDDS towards lipases a slightly modified 
method was used according to Fatouros et al.  (13). Briefly, to obtain lipase 
suspension 50 mg of pancreatic lipase (Type II. 100-400 U/mg) was vortexed for 
3 min in 20 ml cooled digestion buffer without bile salts and subsequently 
centrifuged. The supernatant was recovered and kept at 4 °C to avoid loss of 
enzymatic activity till use for initiation. SEDDS were emulsified to a final 
concentration of 1% (m/v) in digestion buffer composed of 2 mM Trizma, 150 mM 
NaCl, 5 mM CaCl2 and 5 mM bile salts. The temperature of emulsions was set to 
37°C and the pH was adjusted to 6.5 with either 1 M NaOH or 1 HCl. To initiate 
lipolysis freshly prepared lipase suspension was added to emulsion in a ration of 
1:10. After the initiation of lipolysis the pH was kept constant at 6.5 during the cause 
of study by addition of 0.1 M sodium hydroxide and the added amount was 
computed. Considering pH changes are caused by liberated free fatty acids (FFA) 
due to hydrolysis process the amount of added 0.1 M sodium hydroxide can be 
equated with FFA indicating the digestion of SEDDS. The experiment was performed 
for 120 minutes. As a positive control of digestive activity of pancreatic lipase 
Miglyol® 840 was used instead of SEDDS. 
 
2.2.5. Drug release studies and log D SEDDS/release medium determination 
Drug release from SEDDS was assessed via ultrafiltration-centrifugation according 
to a method described previously, but with alterations. For this purpose, 100 µl of 
each anhydrous SEDDS formulation containing octreotide was emulsified in 10 ml 
100 mM phosphate buffer pH 6.8 at 37°C. At predetermined time points, aliquots of 
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500 µl were removed and replaced with an equal amount of fresh release medium. 
After centrifugation in Amicon® Ultra centrifugational filters (Ultracel® 10K) for 
15 minutes at 6000 rpm and 8 °C, the amount of free octreotide in the filtrate was 
quantified via HPLC. Quantification occurred according to a standard curve with 
increasing concentrations of octreotide and cumulative corrections were made for 
previously removed samples. Before usage, filter inserts and collecting tubes were 
stored in 0.1 % (v/v) Tween 80 solution and rinsed extensively with demineralized 
water to avoid adsorption of the peptide to the filter membrane. This procedure was 
verified by centrifugation of a solution of octreotide acetate (c= 0.05 mg/ml) in 
100 mM phosphate buffer and analyzing the content of the peptide in the filtrate. 
Log D SEDDS/release medium representing the likely more informative value regarding the 
in vivo drug release behavior from SEDDS than in vitro drug release profiles (14) 
was obtained by determining maximum solubility in the SEDDS preconcentrates and 
in water. Log D was then calculated by the following equation: 
log D SEDDS / release medium = log (maximum solubility in SEDDS / maximum solubility in water)      (1) 
 
2.2.6. Determination of mucus permeability of SEDDS 
Multiple particle tracking (MPT) technique was used to study the diffusivity of 
different SEDDS through the mucus barrier as described previously (8) (15). Briefly, 
25 µl of lumogen red labelled SEDDS aliquots were inoculated onto a 0.5 g native 
porcine intestinal mucus sample placed in a glass-bottom MatTek imaging dish. 
These samples were incubated for 2 hours at 37 °C to enable uniform distribution of 
droplets within the mucus matrix. The transport of fluorescently labelled droplets was 
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captured in 2-dimensional imaging videos using Epifluorescence microscope (Leica 
DM IRB wide-field Epifluorescence microscope, 63X magnification oil immersion 
lens) supplied with high speed camera (20X digital magnification system, Allied 
Vision Technologies, UK) running at speed rate of 30 frames s-1 and video length of 
300 frames (10 sec). Within each 0.5 g of mucus sample, around 120 droplets were 
simultaneously tracked and their movements were converted into trajectories using 
Fiji ImageJ software. For each SEDDS species, this experiment was carried out in 
triplicate (three different mucus samples with overall 360 individual droplets were 
tracked in three mucus samples). Trajectories were converted into metric distances 
to measure the square displacement of each droplet. The mean square 
displacement MSD of any single droplet is the mean of its square displacements 
through entire 30-frame trajectories (1 second). MSD was determined as follows:  
MSD(n) = (XΔt)
2 + (YΔt)
2                                                                                           (2) 
To define the MSD of all droplets within each mucus sample, ‘‘ensemble mean 
square displacement” (defined by ‹MSD›) was measured by calculating the 
geometric mean of the MSD of the 120 droplets within each sample. Calculating the 
‹MSD› value enables to calculate the effective diffusion coefficient (‹Deff›) for a 
particular SEDDS species following equation 3: 
‹Deff› = ‹MSD›/(4 * Δt)         (3) 
where 4 is a constant relating to a 2-dimensional mode of video capture and Δt is the 
selected time interval. 
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Proportion of diffusive droplets: Each droplet within the sample is defined as diffusive 
droplet if its diffusivity factor (DF) is greater than 0.9 (equation 4), i.e., the division of 
its diffusion at time interval ((Δt) of 1 s over 0.2 s is greater than 0.9.  
DF = Deff Δt=1 s / Deff Δt=0.2 s        (4) 
The proportion of diffusive droplets within a given SEDDS type was then calculated 
and expressed as % Diffusive droplets. 
Heterogeneity in droplet diffusion: Ranking the diffusion coefficients of the 360 
droplets in each SEDDS sample can describe the heterogeneity and the presence of 
outlier sub-populations in each SEDDS species which is indicative of distinctive 
pathways of diffusion through the matrix. To do so, Deff values of 360 droplets at Δt 
of 1 s were ranked from the highest (90th) to the lowest (10th) percentiles, where for 
example the 90th percentile is the Deff value below which 90% of the Deff were 
observed.   
Droplet diffusion in water: The droplets’ diffusion coefficient (D°) in water was 
calculated by the Stokes-Einstein equation at 37 C°:  
[D° = κT / 6πηr]          (5) 
where k is Boltzmann constant, T is absolute temperature, η is water viscosity, r is 
radius of the droplet. The diffusion of all droplets was also expressed as the 
parameter, % ratio [Deff] / [D°]. 
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2.2.7. Permeation through porcine small intestine 
In addition to mucus diffusion studies, permeation enhancing effects of SEDDS 
formulations through the intestinal epithelium were investigated on porcine intestinal 
mucosa according to a method described by Hintzen et al. (16). For this purpose, 
jejunal segments of the small intestine of domestic pigs (sus scrofa domestica) were 
removed after sacrificing. The tissue was rinsed with physiological saline to remove 
luminal contents, cut into pieces of about 1.5 cm in size and mounted on Ussing type 
chambers with a permeation area of 0.64 cm2. One milliliter of HEPES buffer 
(composed of 138 mM NaCl, 1 mM MgSO4, 5 mM KCl, 10 mM glucose, 2 mM CaCl2 
and 10 mM HEPES) served as acceptor medium. The donor compartment was filled 
with 1 ml of 1% (m/v) SEDDS in 100 mM phosphate buffer, pH 6.8 containing 
fluorescence labelled dextran (FD4) in a final concentration of 0.05 % (m/v). 
Thereby, a solution of FD4 (c= 0.05 %) in phosphate buffer was used as control. 
Every 30 minutes, samples of 100 µl were removed from the acceptor compartment 
and replaced by fresh buffer. The cumulative permeated amount of FD4 was 
determined via fluorescence measurement (λex=485 nm and λem=535 nm) using a 
microplate reader (M200 spectrometer; Tecan infinite, Grödig, Austria). 
Quantification occurred according to a standard curve using FD4. 
 
2.2.8. In vivo evaluation of octreotide SEDDS in pigs  
The protocol for the in vivo study in pigs was approved by the Animal Ethical 
Committee of Vienna, Austria (ETK-01/01/2016) and adheres to the Principals of 
Laboratory Animal Care. The in vivo study was performed in 5 male domestic pigs 
(sus scrofa domestica) weighing about 30 kg. Three days prior to the experiment, an 
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indwelling catheter was implanted into the jugular vein under general anesthesia. 
Afterwards, the animals were housed separately, but with nose contact to each 
other. On the day of the experiment, each animal received one formulation 
containing octreotide and all animals were fasted two hours before and one hour 
after administration, but with free access to water. Aliquots (10 ml) of SEDDS 
preconcentrates were administered via a feeding tube followed by 10 ml of apple 
juice. In case of i.v. administration, the formulation was applied via the catheter, 
followed by application of 2 ml of heparinized physiological saline (25 U/ml). At 
predetermined time points, 2 ml of venous blood was removed from the catheter and 
transferred into BD Vacutainer® EDTA tubes. After blood sampling, 2 ml of 
heparinized physiological saline (25 U/ml) were administered to fill the dead volume 
of the cannula and avoid blood clotting within the tube. All blood samples were 
immediately centrifuged for 10 min at 2000 x g at 4 °C to obtain the plasma. The 
plasma samples were stored at -80 °C until analysis via LC-MS/MS as described in 
the following. After a wash out phase of minimum 24 hours, the animals were dosed 
again, whereby the assignment of formulations and animals occurred in a 
randomized manner. In total, each animal was dosed four times. An overview over 
the experimental setup is provided in Table 2. 
 
2.2.9. Quantification of octreotide via LC-MS/MS 
Octreotide was quantified in plasma samples from the in vivo study using LC-
MS/MS. The analysis was carried out on a 3200 QTRAP (Sciex, Framingham, MA,  
USA) equipped with a Knauer K-1001 HPLC Pump (Berlin, Germany), a PAL HTC 
autosampler (CTC Analytics, Zwingen, Switzerland) with a 20 µl loop, and a column 
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thermostat (Thermotechnic Products GmbH, Langenzersdorf, Austria). The mobile 
phase was composed of: A: 95 % water, 5 % MeOH, 0.5 % acetic acid, 0.05 % 
HFBA and B: 5 % water, 95 % MeOH, 0.5 % acetic acid, 0.05 % HFBA. The samples 
were separated on a XB-C18 Aeris wide-pore column (3.6 µm, 150 x 210 mm, 
Phenomenex Aschaffenburg, Germany) using gradient elution with a linear gradient 
from 0 – 100 % B in 10 minutes at a flow rate of 0.2 ml/min, an oven temperature of 
50 °C and an injection volume of 10 µl. Mass spectrometric detection was performed 
in positive ion mode. The spray voltage was set to 5500 V, Gas flows of 50 arbitrary 
units for the nebulizer gas and 25 arbitrary units for the turbo gas were used. The 
temperature of the turbo gas was adjusted to 500 °C. Multiple reaction monitoring 
was performed using the precursor-to-product ion transitions of the doubly charged 
octreotide at 510.4 > 120.2 and the doubly charged octreotide-D8 at 514.4 > 120.2. 
The collision energy was set to 35 eV, and the dwell time to 100 ms. Chromatograms 
and mass spectra were recorded on a personal computer with Analyst 1.5 software 
(AB Sciex). 
 
2.2.10. Standard samples and sample preparation 
For the quantification of octreotide, octreotide-D8 was used as internal standard (IS). 
For calibrators, stock solutions containing 1.0 mg/ml of octreotide or the IS were 
prepared in methanol and stored at -20 °C until use. Working standards of octreotide 
in the concentration range 50-1000 ng/ml were prepared by dilution of the stock 
solutions with water. The working solution of the IS was prepared by diluting the 
octreotide-D8 stock solution with water to a final concentration of 100 ng/ml. 
Calibration samples were prepared by spiking 250 µl of plasma with 25 μl IS working 
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solution and aliquots of the octreotide working solutions to obtain ten different 
concentration levels: 0 ng/ml, 0.5 ng/ml, 1 ng/ml, 2.5 ng/ml, 5 ng/ml, 10 ng/ml, 25 
ng/ml, 50 ng/ml, 100 ng/ml, and 500 ng/ml.  
250 µl of in vivo study samples were spiked with 25 μl IS working solution. Samples 
were mixed with 250 µl of 4 % H3PO4 prior to extraction. Octreotide and the IS were 
isolated from plasma samples via solid phase extraction using a WXC column (1cc, 
10 mg sorbent, Waters, Milford, MA, USA). Prior to use, the column was equilibrated 
with 1 ml methanol followed by 1 ml of distilled water. Then, the sample was loaded 
onto the column. Afterwards, the column was washed with 500 µl 5 % NH4OH 
followed by 500 µl 20 % ACN and the column was vacuum-dried for 5 min. Then, 
octreotide was eluted with 500 µl of a mixture of 75 % ACN and 25 % water with 1 % 
TFA. In the end, the solvent was evaporated under nitrogen flow at room 
temperature and the residue was dissolved in 25 µl of sample solvent (80 % water, 
20 % MeOH, 0.5 % acetic acid, 0.05 % HFBA). The samples were analyzed for 
octreotide and IS via LC-MS/MS as described above.  
 
2.3. Statistical data analyses 
Statistical data analysis was performed using one way Anova with Bonferroni post-
hoc test and with 95 % confidence interval (p<0.05). Results are expressed as the 
means of at least three experiments ± standard deviation. 
 
15 
 
3. Results 
3.1. Hydrophobic ion pairing of octreotide 
Ionic interactions between the positively charged octreotide and the negatively 
charged surfactants led to formation of water insoluble complexes, visible as white 
precipitate. Within the investigated range, a molar ratio of 1:3 (peptide to surfactant) 
was shown to precipitate the highest amount of octreotide. Results of this study are 
illustrated in Fig. 2.  
 
3.2. Preparation and characterization of SEDDS 
In order to avoid degradation of SEDDS droplets by lipases, Brij O10, propylene 
glycol and octyldodecanol exhibiting no ester structures were chosen. Addition of 
ethanol to this composition led to a decreased droplet size. By diluting the pre-
concentrates with 100 mM phosphate buffer in a ratio of 1:100, dark bluish 
emulsions were formed. The incorporation of the different hydrophobic ion pairs had 
a significant impact on droplet size and stability of SEDDS. In order to obtain SEDDS 
of similar composition, size, zeta potential and stability, numerous ratios of 
surfactants, solvents and co-solvents were tested (data not shown). Out of these 
formulations, SEDDS B3, B4 and B6 as listed in Tab. 1 were chosen representing 
the likely best compromise. In particular, size and zeta potential of these 
formulations was of minor difference. Furthermore, degradation studies with lipase 
demonstrated that none of these SEDDS is degraded at all, whereas the control was 
entirely degraded within 2 hrs.  
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3.3. In vitro drug release and log D SEDDS/release medium 
In vitro release studies of octreotide out of SEDDS formulations were assessed for 
the different ion pairs. Formulations containing octreotide-deoxycholate and 
octreotide-decanoate exhibited a comparatively fast drug release, as the peptide was 
completely released within the first three hours. In contrast, SEDDS loaded with 
octreotide-docusate showed a prolonged release for more than six hours. Time 
dependent release profiles are depicted in Figure 3. During centrifugation drug 
release caused by mechanical deformation of the SEDDS droplets was not an issue, 
as no octreotide could be detected in the filtrate at t0. Log D values of octreotide-
deoxycholate, -docusate and –decanoate were determined to be 1.7 ±0.3, 1.8 ±0.4 
and 2.7 ±0.3 (n=3). 
 
3.4. Mucus diffusion studies 
Interactions between SEDDS and mucus were investigated via multiple particle 
tracking. Table 3 shows MPT diffusion data [cm2 S-1 x 10-9] in the native intestinal 
mucus model <Deff> and in water D° (calculated by Stokes Einstein equation); the 
ratio of < Deff> to D° expressed as a %; and in the last column, the % of diffusive 
droplets. The <Deff> is a measure of the absolute diffusion of the droplets through 
mucus reflecting both surface chemistry and droplet size, while the % ratio <Deff>/D°  
is a measure of the diffusion of the droplets through mucus with respect to surface 
chemistry characteristics alone, i.e. normalized against differences in droplet size.  
Accordingly, Figure 4 shows the effect of the physicochemical properties of SEDDS 
on their diffusivity. These effects presented as follows: Figure 4A shows the <Deff> 
versus the droplet size data for the respective SEDDS, Figure 4B shows the<Deff> 
versus the zeta potential for the respective SEDDS and Figure 4C shows the 
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%<Deff>/D of each of the SEDDS versus zeta potential. It can be seen that SEDDS 
B4 showed the highest <Deff> compared with other systems. However, normalizing 
the droplet size effect by calculating %<Deff>/D° shows that formula B6 is more 
diffusive through mucus compared with other formulae. Figure 1S describes the DF 
and the ratio of diffusive droplets which is shown in Table 3. This figure shows that 
among 20 droplets selected randomly, 7 droplets were diffusive for sample B6 while 
only 4 droplets were diffusive in sample B3. Figure 5 describes the degree of 
heterogeneity of droplets diffusion through the mucus. For each droplet types, the 
Deff of 360 individual droplets at 1sec were ranked into percentiles to allow the 
comparison of the slowest (10th) percentiles to the fastest (90th) percentiles which is 
defined as the Deff value below which 90% of the Deff values within the droplet 
population occur. Figure 5 shows that all systems have a high heterogeneity of 
droplets diffusion. This can be seen obviously with SEDDS B6 which showed a 
sharp difference in the Deff of droplets with 40% percentile compared with Deff at 
30% percentiles. This high heterogeneity reflects the presence of more than one 
mechanism of interaction of droplets within the mucus matrix resulted in presence of 
different populations of droplets with huge difference in their diffusion properties. 
 
3.5. Ex vivo permeation through porcine small intestine 
Ex vivo permeation experiments through freshly excised porcine intestinal mucosa 
were carried out using the model compound FD4 as described previously by Hintzen 
et al. (16). The cumulative transport of the hydrophilic and macromolecular FD4 is 
shown in Figure 6. In presence of SEDDS the transport of FD4 could be strongly 
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improved. These data are in agreement with various previous studies demonstrating 
a permeation enhancing effect of SEDDS for hydrophilic macromolecules. 
 
3.6. In vivo evaluation of octreotide SEDDS 
Results of in vivo studies with different octreotide SEDDS and a solution of the 
peptide in apple juice in pigs are summarized in Table 4. After oral administration, 
octreotide was taken up into the systemic circulation from octreotide-deoxycholate 
SEDDS and SEDDS containing octreotide-docusate. In contrast, administering the 
peptide in a solution in apple juice and octreotide-decanoate in form of SEDDS 
resulted in comparatively low plasma concentrations. In case of all oral formulations, 
the maximum plasma concentration could be observed after 60 minutes as illustrated 
in Fig. 7. Octreotide-deoxycholate SEDDS and octreotide-docusate SEDDS showed 
a 17.9-fold and 4.2-higher relative bioavailability, compared to the solution in apple 
juice. In contrast, oral bioavailability was not increased by octreotide-decanoate 
SEDDS (Table 4). 
 
4. Discussion 
Ion pairing with sodium deoxycholate, sodium decanoate and sodium docusate in 
different molar ratios (1:1, 1:2, 1:3, 1:4) resulted in a decreased water solubility of the 
peptide. Within this study, the ratio of 1:3 was shown to be most efficient to prepare 
ion pairs of octreotide, as nearly quantitative precipitation of octreotide was feasible 
(Figure 2). As octreotide exhibits two cationic substructures as illustrated in Fig. 1, a 
molar ratio of 1:2 should already saturate both of these cationic substructures. Our 
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results, however, showed that a ratio of 1:3 is more efficient. These data are in 
agreement with previous studies demonstrating that either an equivalent or slightly 
higher ratio is most efficient for HIP formation (6). Because of its D-amino acids and 
due to its cyclic structure, octreotide is stabilized against degradation by intestinal 
proteases (17). In order to exclude also the degradation of SEDDS in the small 
intestine, lipase stable SEDDS were developed. In general, lipases are endogenous 
enzymes present in the pancreatic fluid being responsible for the degradation of 
nutritional fats. However, these enzymes are also capable of degrading ester 
structures of SEDDS components resulting in a premature release of the 
incorporated peptide (7) (18). Drug release studies from lipase stable SEDDS 
revealed a clear correlation between the lipophilicity of the surfactant and the 
corresponding release kinetic. An increasing lipophilicity of the ion pairing agent 
resulted in a decelerated drug release. Formulations containing octreotide-
decanoate showed the fastest release among the investigated formulations (Figure 
3). Exhibiting only 10 carbon atoms, decanoate is considerably less lipophilic 
compared to deoxycholate with 24 carbon atoms and docusate with 20 carbon 
atoms, leading to a shorter residence time within the lipophilic SEDDS droplets. As 
the release from SEDDS with octreotide-deoxycholate was faster than from 
formulations with the docusate ion pair, also the structure of the utilized compound 
seems to have an impact. With two branched octyl- residues, docusate might have a 
greater lipophilic surface area compared to the cyclic bile salt deoxycholate, resulting 
in an extended retention in the lipophilic phase. These observations are also in good 
agreement with the determined log D values, as the octreotide-decanoate ion pair 
exhibiting the fastest drug release showed a log D of 1.7, whereas the octreotide-
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docusate ion pair exhibiting the most sustained drug release showed the highest log 
D of 2.7. 
A further requirement for efficient drug delivery systems is the ability to overcome the 
mucus barrier in the intestinal compartment, as the mucus gel layer represents a 
major obstacle, drug delivery systems have to overcome it to reach the underlying 
epithelia (19). Octreotide might pass the mucus barrier within the SEDDS droplets 
more efficiently, leading to a higher concentration at the absorptive membrane. At an 
intestinal pH value of around 6.8 octreotide is positively charged due to its basic 
amino acids. As the mucus layer is negatively charged, ionic interactions between 
the peptide might restrict permeation. On the other hand, being incorporated into 
SEDDS droplets and having a neutral charge in form of the respective ion pair, might 
shield the peptide from ionic interactions and allow passaging the mucus barrier. 
Accordingly, mucus diffusive properties of SEDDS formulations were studied via 
multiple particle tracking. In general, SEDDS have two main inter-independent 
variables that can affect the diffusion of these systems through the mucus. These 
are: the physicochemical properties of the SEDDS and the ingredients in each 
system. Figure 4A shows that droplet sizes ranging from 100 up to 250 nm do not 
correlate with the corresponding <Deff>. Similarly, Figure 4B and 4C failed to reveal 
any correlation of zeta potential to <Deff> or %ratio <Deff>/D° respectively, where all 
systems have close zeta potential values but different diffusivities. This finding is in 
agreement with previous reported work where the physicochemical properties had 
no effect on the diffusivity of SEDDS (8). Table 3 and Figure 4, however, do show 
that the SEDDS are affected by their formulation ingredients. Thus, Figure 4C shows 
that SEDDS B6 which has no ethanol as a co-surfactant within the ingredients has 
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the highest diffusivity (% Ratio <Deff>/Do 0.5917) as compared with the other types 
of SEDDS having ethanol at ratios of 1.5 and 5%.  
Moreover, Table 3 presents the % of diffusive droplets of SEDDS within the mucus. 
As described earlier, DF is the term defines the diffusive droplets as the droplets for 
which the Deff at 1 second is ≥ 90% of the Deff at the 0.2 second. This definition 
means that only diffusive droplet will show an increase in the diffusion within time. 
This is based on the concept that increase of time interval will increase the chances 
of trapping media to interact with droplets transporting through it. Table 3 shows that 
37% of droplets of SEDDS B6 were identified to be diffusive through the mucus while 
32% and 24% of droplets were identified to be diffusive for SEDDS B4 and SEDDS 
B6, respectively. Figure 4 clarifies this behavior for 20 randomly selected droplets 
from a total of 360 droplets of SEDDS B3 and SEDDS B6. It can be seen that 7 of 
the randomly selected 20 droplets (35%) of SEDDS B6 showed an increase in the 
diffusion within time interval increase from lower to higher points. Similarly, for 
SEDDS B3, 4 droplets of the selected 20 droplets (20%) showed diffusive properties 
through mucus. It can be seen that the difference in the % Ratio <Deff>/Do between 
systems is not directly related to the percent of the diffusive droplets of these 
systems, for example, the increase of % Ratio <Deff>/Do by 5 times (from 0.1247 to 
0.5917) between systems B3 and B6 is accompanied by 1.5 times increase in % of 
diffusive droplets for the same systems. This indicates that the droplets which 
categorised as non-diffusive have higher effect than the diffusive droplets on the final 
diffusion coefficient of the systems. This is in accordance with Figure 5 which 
showed almost 60 percentile of droplets of all SEDDS species have much slower 
diffusion through mucus compared with the fastest 20 percentile. 
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As limited absorption from the intestinal mucosa is a main reason for the low oral 
bioavailability, permeation enhancing properties of SEDDS would be favorable (3). 
Studying the permeation of the hydrophilic and high molecular weight marker FD4 
showed that in presence of all SEDDS formulations, the transport through porcine 
intestinal mucosa was distinctly increased (Figure 6), most likely due to a tight 
junction opening in presence of SEDDS. Decrease in cell-cell junction activity was 
already described for self-emulsifying systems containing surfactants with a high 
HLB value (20), such as Cremophor EL (16) or Tween 80 (21). Similarly, Brij O10 
with a HLB value of 12.4 might have caused a loosening of the tight junctions 
resulting in an increased permeation of FD4.  
Finally, SEDDS formulations loaded with octreotide ion pairs were investigated in 
vivo. Due to anatomical and physiological similarities to humans (22), pigs were 
chosen for the in vivo study. Oral administration of a solution of octreotide-acetate 
proved that the peptide is poorly absorbed (Cmax=4.28 ng/ml) from the gastro-
intestinal tract, which is most likely due to a low permeability across the intestinal 
mucosa. However, applying octreotide ion pairs in SEDDS resulted in a 
comparatively higher bioavailability (Table 4). Moreover, the absorption was more 
sustained compared to the solution (Figure 7). These results are in good accordance 
with a previous in vivo study in rats, in which administration of leuprolide SEDDS 
resulted in an increased oral bioavailability and an extended absorption compared to 
an aqueous solution of the peptide (4). Within the current study, however, these 
findings could only be observed for SEDDS containing octreotide-deoxycholate and 
octreotide-docusate. Accordingly, oral uptake of peptides from SEDDS into the 
systemic circulation is strongly dependent on the type of HIP. 
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On the one hand, the release behavior of the different ion pairs from SEDDS has 
certainly an important impact on their in vivo performance. SEDDS containing 
octreotide-deoxycholate showed more than 4-fold higher octreotide plasma levels 
than SEDDS with octreotide-docusate being comparatively more sustained released.  
Accordingly, a peptide release from SEDDS within 2-3 hours seems to be favorable 
in order to achieve a high uptake into the systemic circulation. In contrast, an 
immediate release seems to be disadvantageous as well, as octreotide-decanoate 
being most rapidly released from SEDDS could not improve oral bioavailability 
compared to an aqueous solution. 
On the other hand, the intrinsic properties of the anionic surfactants used for ion 
pairing might have an impact on the performance of HIPs. The inferior performance 
of SEDDS containing octreotide-docusate might also be attributed to the 
pharmacological effect of docusate. Stimulating secretion and inhibiting fluid 
absorption in the jejunum, uptake of octreotide might be reduced in presence of this 
surfactant. Furthermore, deoxycholate was shown to enhance the oral bioavailability 
of nanocarriers (23). The responsible mechanism seems to be based on a bile acid 
pathway allowing overcome of the intestinal epithelium (24). 
Comparing the oral bioavailability of 5.2% having been achieved with SEDDS 
containing the octreotide-deoxycholate ion pair with that of so far established 
formulations allows an estimation of its efficacy. Using the Intravail®-technology, a 
relative oral bioavailability of 4.0% vs. subcutaneous administration was achieved in 
mice (25). In another study a relative oral bioavailability of 2.3% vs. subcutaneous 
administration was determined in monkeys when an oily suspension formulation 
containing the well-established permeation enhancer sodium caprylate was used 
(26). As the subcutaneous bioavailability of octreotide is just around 30% of its 
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intravenous bioavailability (17), the maximum oral bioavailability obtained with the 
octreotide-deoxycholate ion pair is even 4.3-fold and 7.5-fold higher. Being aware of 
that just three different ion pairs were tested within this study and SEDDS containing 
HIPs have not yet been optimized, demonstrates the likely great potential of this 
technology for oral peptide delivery. 
 
Conclusions 
Within this study, lipase stable SEDDS containing different hydrophobic ion pairs 
were generated. Due to the stability of the carrier system and the cargo drug against 
enzymatic degradation, the influence of these ion pairs on oral bioavailability could 
be elucidated. Deciding over mucus permeability, protection against enzymatic 
degradation, as well as absorption into the systemic circulation, it could be 
demonstrated, that the type of hydrophobic ion pairing is a key parameter for the in 
vivo performance of peptide loaded SEDDS. Moreover, the distinctly improved oral 
bioavailability of octreotide in pigs in the range of 5%, triggered by an administration 
via SEDDS, supports findings of previous in vivo studies in rodents. Thus, this study 
does not only provide evidence for the importance of the type of ion pair but is also a 
proof of concept that HIPs being incorporated in SEDDS are a promising strategy in 
the field of oral peptide delivery.  
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Table 1. Composition, droplet size polydispersity index (PI) and zeta potential of 
SEDDS  
No	 Composition	in	%	(v/v)	
	
	
HIP	in	%	(m/v)	
																
Mean	
droplet	
size	
(nm)	
		
		
PDI	
		
		
Zeta	
potential	
(mV)	
		
		
		 Surfactant	 Co-solvent	 Oily	component	
		 Brij	O10	
Propylene	
glycol	
Ethanol	 Paraffin	
Octyl-
dodecanol	
B1	 30	 8.5	 1.5	 30	 30	 ---	 110	 0.329	 -3.48	±	0.83	
B2	 50	 10	 1.5	 10	 28.5	 ---	 173	 0.205	 -4.33	±	0.76	
B3	 40	 10	 1.5	 		 48.5	 ---	 179	 0.258	 -4.81	±	0.44	
B3	 40	 10	 1.5	 		 48.5	
0.5	(octreotide-
deoxycholate)	
152	 0.16	 -3.71	±	0.43	
B4	 40	 15	 5	 		 40	 ---	 105	 0.18	 -3.54	±	0.31	
B4	 40	 15	 5	 		 40	
0.5	(octreotide-
decanoate)	
112	 0.18	 -4.56	±	0.46	
B5	 50	 10	 1.5	 		 38.5	 ---	 187	 0.168	 -3.80	±	0.30	
B6	 60	 10	 		 		 30	 ---	 151	 0.151	 -3.63	±	0.49	
B6	 60	 10	 		 		 30	
0.5	(octreotide-
docusate)	
191	 0.15	 -5.72	±	0.83	
 
Table 2. Overview on formulations utilized for  in vivo studies in pigs 
Formulation No Route of 
administration 
Dose Dosage 
Form 
Volume 
Octreotide acetate 
aqueous solution 
 intravenous 750 µg Aqueous 
solution 
5 ml 
Octreotide solution in 
apple juice 
 oral 50 mg --- 10 ml 
Octreotide-deoxycholate 
SEDDS 
B3 oral 50 mg SEDDS 10 ml 
Octreotide-decanoate 
SEDDS 
B4 oral 50 mg SEDDS 10 ml 
Octreotide-docusate 
SEDDS 
B6 oral 50 mg SEDDS 10 ml 
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Table 3. Zeta potential, droplet size, Diffusion coefficient in water and mucus and 
percentage (%) of diffusive droplets of various SEDDS preparations. Mucus diffusion 
was measured by the MPT technique using the Epifluorescence microscopy while 
diffusion in water was obtained through Stokes-Einstein equation 
 
 
 
 
 
 
 
 
 
Table 4. Pharmacokinetic parameters calculated after i.v. and oral administration of 
investigated octreotide formulations in pigs. Relative bioavailability was calculated 
with reference to i.v. formulations. Indicated values are means of 4 pigs. 
 
  
SEDDS D
o
 (water) 
cm
2
.S
-1 
x 10
-9
 
<Deff> (mucus) 
cm
2
.S
-1 
x 10
-9
 
Mean ( +s.e.m) 
% Ratio 
<Deff>/D
o
 
% 
Diffusive 
droplets 
B3 26.59 
0.03315 
(±0.00526 ) 
0.1247 24 
B4  44.5 
0.16793 
(±0.03762) 
0.3774 32 
B6 17.76 
0.10509 
(±0.02555) 
0.5917 37 
Delivery system No AUC 
(min*ng/ml) 
Cmax 
(ng/ml) 
tmax 
(min) 
% Relative 
bioavailability 
i.v. solution  656.01 100.10 - - 
Octreotide-deoxycholate 
SEDDS  
B3 2277.96 74.22 60 5.21 
Octreotide-decanoate 
SEDDS  
B4 133.83 3.94 60 0.31 
Octreotide-docusate 
SEDDS  
B6 530.62 17.15 60 1.21 
Octreotide in apple juice  128.48 4.28 60 0.29 
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Fig. 1. Chemical structure of octreotide and the anionic counter ions. 
 
 
 
Figure 2. Comparison of remaining octreotide acetate in the water phase in relation 
to the amount of counter ion (black bars = sodium decanoate; grey bars = sodium 
deoxycholate; white bars = sodium docusate); indicated values are means ±SD 
(n=3);   
 
         Octreotide 
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Figure 3. Illustration of release profile for SEDDS containing octreotide ion pairs. 
Time dependent drug release of octreotide-deoxycholate (■), octreotide-decanoate 
(♦) and octreotide-docusate (●) in 100 mM phosphate buffer pH 6.8 at 37°C. 
Depicted values are the means of at least three experiments ± standard deviation. 
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Figure 4. Correlation of droplet size and surface charge of various SEDDS to their 
mucus diffusion. (A) Correlation of droplet size of various SEDDS versus <Deff>. (B) 
Correlation of zeta potential of various SEDDS versus <Deff>. (c) Correlation of zeta 
potential of various SEDDS versus the % ratio of <Deff>/D°. Droplet size is 
expressed in nm, zeta potential is expressed in mV and Deff is measured in cm2. s-1 
*109. 
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Figure 5. Comparison of average Deff of SEDDS B3, SEDDS B4 and SEDDS B6 at 
a time scale of 1 sec in mucus of subclasses from the fastest to the slowest 
percentile. Figure presents data of 3 experiments each with n ≥ 120 droplets. 
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Figure 6. Permeation of FD4 across porcine small intestinal mucosa. Cumulative 
transport of FD4 in 0.1 M phosphate buffer pH 6.8 at 37°C in presence of 1.0% 
SEDDS-formulation B3 (■), 1.0% SEDDS-formulation B4 (♦) and 1.0% SEDDS-
formulation B6 (●) vs. buffer only (▲). Indicated values are means (± SD, n=3) 
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Figure 7. (A) Plasma concentration of octreotide after intravenous injection of 
octreotide acetate (dose is 750 µg) to pigs. (B) Plasma concentration curves of 
octreotide after administration of an octreotide acetate solution (▲), octreotide-
deoxycholate SEDDS (■), octreotide-decanoate SEDDS (♦) and octreotide-docusate 
SEDDS (●) to pigs (dose = 50 mg). Indicated values are means from 4 applications ± 
SD. 
B 
A 
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Supplementary Figures: 
 
 
Figure 1S: Effective diffusivities Deff versus time scale of 20 randomly selected 
droplets selected by (random.org). (A) SEDDS B6: high ratio of droplets shows 
diffusivities. (B) SEDDS B3: Some droplets are diffusive vs major restricted droplets.   
 
